Biotechnology - Anti-virals, Pharmaceutical

Filter

Current filters:

Anti-viralsPharmaceutical

Popular Filters

1 to 25 of 62 results

Janssen-Cilag files European approval of combination medicine for HIV-1

16-10-2013

US health care giant Johnson & Johnson subsidiary Janssen-Cilag International NV has submitted a Marketing…

Anti-viralsBiotechnologycobicistatDarunavirEuropeGilead SciencesJanssen-CilagJohnson & JohnsonPharmaceuticalRegulation

AHF claims victory over FDA in HIV prevention drug case

08-08-2013

The USA-based AIDS Healthcare Foundation (AHF) says it won a key legal victory in a push for drug safety…

Anti-viralsBiotechnologyGilead SciencesLegalNorth AmericaPharmaceuticalRegulationTruvada

Vertex slumps as FDA delays hepatitis C trial

26-07-2013

US drug maker Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares drop 11% to $78 a share, in after-hours…

Anti-viralsBiotechnologyNorth AmericaPharmaceuticalRegulationResearchVertexVX-135

New Zealand consults on Victrelis listing and some Pegasys amendments

19-07-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list boceprevir…

Anti-viralsAsia-PacificBiotechnologyMerck & CoPegasysPharmaceuticalRegulationRocheVictrelis

UK's NICE recommends hepatitis C treatment for children

18-07-2013

In draft guidance published this week, the UK's drugs watchdog the National Institute for Health and…

Anti-viralsBiotechnologyEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferonPeg

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs

09-07-2013

Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…

Anti-viralsBiotechnologyGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearch

BioLineRx collaborates with Chinese firm on hep C drug BL-8030

11-06-2013

Israeli drug developer BioLineRx (TASE: BLRX) has signed an out-licensing agreement with Jiangsu Chia-tai…

Anti-viralsAsia-PacificBioLineRxBiotechnologyBL-8030Chia-tai Tianqing PharmaceuticalLicensingPharmaceutical

Negative FDA news for AVEO's tivozanib and Dynavax' hep B vaccine

11-06-2013

US biotech firm AVEO Oncology (Nasdaq: AVEO) says that it has received a complete response letter from…

Anti-viralsAstellas PharmaAVEO OncologyBiotechnologyDynavax TechnologiesHeplisavNorth AmericaOncologyPharmaceuticalRegulationtivozanibVaccines

AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA

22-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday (May 21) presented the results of two pivotal…

Anti-viralsAstraZenecaBiotechnologyEuropeGastro-intestinalsGilead SciencesnaloxegolNektar TherapeuticsPharmaceuticalRegulationResearchsofosbuvir

HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst

20-05-2013

While the risks involved in HIV vaccine development have turned Big Pharma away from pursuing a preventative…

Anti-viralsBiotechnologyFinancialHVTN 505PharmaceuticalResearchVaccines

Encouraging results with Sangamo's SB-728-T in HIV treatment

15-05-2013

USA-based Sangamo BioSciences (Nasdaq: SGMO) has presented new clinical data from its program to develop…

Anti-viralsBiotechnologyPharmaceuticalResearch

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx

06-05-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

US and European gastroenterologist's views on hepatitis C treatments

02-05-2013

Gastroenterologists in the USA and Europe by health care advisory firm Decision Resources agree that…

Anti-viralsBiotechnologyEuropeMarkets & MarketingNorth AmericaPharmaceuticalResearch

Janssen files for European approval of hep C candidate simeprevir

25-04-2013

Janssen-Cilag International, a European subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ),…

Anti-viralsBiotechnologyEuropeJanssen-CilagJohnson & JohnsonPharmaceuticalRegulationsimeprevir

Highlights of presentations from Bristol-Myers, J&J, Gilead and AbbVie at EASL meeting

24-04-2013

Among a number of drug and biotech majors planning to present at the 2013 annual meeting of the European…

AbbVieAnti-viralsasunaprevirBiotechnologyBristol-Myers SquibbdaclatasvirGilead SciencesJohnson & JohnsonPharmaceuticalResearchsimeprevirsofosbuvir

Roche teams up with Ascletis on hep C treatments for China

15-04-2013

Roche (ROG: SIX) has entered a collaboration with Ascletis Pharmaceuticals, a USA- and China-based biotech…

Anti-viralsAscletis PharmaceuticalsAsia-PacificBiotechnologydanoprevirLicensingMarkets & MarketingPharmaceuticalResearchRoche

Specialty drug costs account for over 50% of the total cost of care for RA and hepatitis C patients in USA

03-04-2013

According to two new studies by Prime Therapeutics, a leading US pharmacy benefit manager, rheumatoid…

Anti-Arthritics/RheumaticsAnti-viralsBiotechnologyFinancialHealthcareNorth AmericaPharmaceutical

News briefs: Pfizer's filiburvir; Sanofi's Plavix; EMA sued over transparency

11-03-2013

Among a batch of news reported over the weekend, US drugs behemoth Pfizer (NYSE: PFE) has halted development…

AbbVieAnti-Arthritics/RheumaticsAnti-viralsBiotechnologyCardio-vascularEuropefiliburvirHumiraInterMuneNorth AmericaPfizerPharmaceuticalPlavixRegulationResearchSanofi

1 to 25 of 62 results

Back to top